[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-detail-350554-en":3,"doc-seo-350554-105":51,"detail-sidebar-cat-0-en-105":116},{"code":4,"msg":5,"data":6},0,"success",{"doc_id":7,"user_id":8,"nickname":9,"user_avatar":10,"doc_module":4,"category_id":11,"category_name":12,"doc_title":13,"doc_description":14,"doc_content":15,"file_id":16,"file_url":17,"file_type":18,"file_size":19,"view_count":20,"is_deleted":4,"is_public":21,"is_downloadable":21,"audit_status":21,"page_count":22,"language":23,"language_code":24,"site_id":25,"html_lang":24,"table_of_contents":26,"faqs":27,"seo_title":28,"seo_description":14,"update_tm":29,"read_time":30,"preview_page_count":31,"preview_urls":32},350554,7421720224475,"Mary Man","https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c",8,"Research & Report","Complications in patients with cancer-associated thrombosis on tinzaparin by cancer site and frailty: a pooled analysis","Cancer-associated thrombosis (CAT) is a common and severe complication in malignancy, yet recurrence and bleeding risks are often evaluated as a single group in trials despite major heterogeneity by tumor type and patient frailty. This pooled individual patient data meta-analysis assessed 6-month incidences of recurrent VTE, major bleeding, and death in CAT patients treated with tinzaparin, analyzing how tumor site and frailty influence these outcomes.","REGULAR ARTICLE  \nComplications in patients with cancer-associated thrombosis on tinzaparin by cancer site and frailty: a pooled analysis  \nIsabelle Mah´e, 1-4,* C´eline Chapelle,5, 6,* Philippe Girard,4, 7 Luis Jara-Palomares,8 Agnes Y. Y. Lee,9, 10 Olivier Sanchez,1,3,4, 11 Guy Meyer,4, 11 Patrick Mismetti,4,5, 12 and Silvy Laporte4-6  \n1 Paris Cit´e University, Paris, France; 2 Department of Internal Medicine, Louis Mourier Hospital, Assistance Publique–Hˇopitaux de Paris, Paris, France; 3Team Endotheliopathy and Hemostasis Disorders, Paris Cardiovascular Research Center, INSERM UMR-S970, Paris, France; 4 F-CRIN INNOVTE Network, Saint- ´Etienne, France; 5 INSERM Unit´e 1059, Sant´e Ing´enierie Biologie Saint- ´Etienne, Mines Saint- ´Etienne, Universit´e Jean Monnet, Saint- ´Etienne, France; 6 Service de Pharmacologie Clinique, CHU de Saint-´Etienne, Saint- ´Etienne, France; 7 D´epartement de Pneumologie, Institut Mutualiste Montsouris, Paris, France; 8 Medical Surgical Unit of Respiratory Diseases, Instituto de Biomedicina de Sevilla, Centro de Investigaci´on Biom´edica en Red de Enfermedades Respiratorias, Hospital Universitario Virgen del Rocio, Seville, Spain; 9The University of British Columbia, Vancouver, BC, Canada; 10 BC Cancer, Vancouver, British Columbia, Canada; 11 Service de Pneumologie et Soins Intensifs, Hˇopital Europ´een Georges Pompidou, Assistance Publique–Hˇopitaux de Paris, Paris, France; and 12 Service de M´edecine Vasculaire et Th´erapeutique, CHU Saint- ´Etienne, Hˇopital Nord, Saint- ´Etienne, France  \nKey Points  \n• In patients with CAT treated with tinzaparin, VTE recurrence risk varies by tumor site and frailty, whereas bleeding risk remains stable.  \n• This individual patient data meta-analysis supports standarddose tinzaparin in CAT, regardless of tumor site or frailty.  \nCancer-associated thrombosis (CAT) is a frequent and severe complication of malignancy. Although patients undergo anticoagulation, risks of recurrent venous thromboembolism (VTE) and major bleeding (MB) remain substantial, but data are limited according to specific tumor sites and in patients with frailty. Our objective was to evaluate 6-month incidences of recurrent VTE, MB, and death in patients with CAT treated with tinzaparin, and to assess the influence of tumor site and frailty on these risks. Individual patient-level data from 1413 patients were pooled from 3 prospective cohort studies and the tinzaparinarm of a randomized controlled trial. Frailty was defined as age of ≥75 years, creatinine clearance of \u003C50 mL/min, body weight of ≤50 kg, or Eastern Cooperative Oncology Group performance status of ≥2. Cumulative incidences were estimated using Kalbfleisch and Prentice method and plotted to illustrate the benefit-risk balance by tumor site and frailty. At 6 months, cumulative incidences of recurrent VTE and MB were 6.2% and 3.4%, respectively. Recurrent VTE incidence surpassed MB incidence in gastrointestinal, lung, genitourinary, and gynecological cancers, whereas MB risk exceeded VTE risk in breast cancer. Among patients with frailty criteria, recurrent VTE risk increased with the number of frailty factors, whereas MB remained relatively stable. In patients with CAT receiving tinzaparin, VTE recurrence, unlike bleeding risk, varies according to tumor site and patient frailty. In frail patients with CAT treated with standard full-dose tinzaparin, these findings do not support routine dose modification.  \nIntroduction  \nCancer-associated thrombosis (CAT) is a frequent and severe complication of malignancy, yet it is often treated as a single population in randomized controlled trials, despite encompassing a highly heterogeneous group of patients with different tumor types and distinct clinical characteristics. Although patients undergo anticoagulation, the risks of recurrent venous thromboembolism (VTE) and  \nSubmitted 1 December 2025; accepted 29 January 2026; prepublished online on Blood Advances First Edition 18 Februar","cbCaioaT35mhkjOs","https://ap.wps.com/l/cbCaioaT35mhkjOs","pdf",556311,11,1,9,"English","en",105,"# Key Points\n# Objective and Methods\n## Frailty Definition\n## Outcomes and Statistical Approach\n# Results\n## 6-Month Incidence by Cancer Site\n## Effect of Frailty on VTE and Bleeding\n# Conclusion\n# Introduction","[{\"question\":\"What outcomes were evaluated in CAT patients treated with tinzaparin?\",\"answer\":\"The analysis evaluated 6-month incidences of recurrent VTE, major bleeding, and death, and compared how these outcomes vary by tumor site and frailty.\"},{\"question\":\"How was frailty defined for this study?\",\"answer\":\"Frailty was defined by age ≥75 years, creatinine clearance \\u003c50 mL/min, body weight ≤50 kg, or Eastern Cooperative Oncology Group performance status ≥2.\"},{\"question\":\"Do tumor site and frailty affect VTE recurrence and bleeding differently?\",\"answer\":\"VTE recurrence risk varied by tumor site and frailty, while bleeding risk remained relatively stable across these factors.\"}]","Complications in patients with cancer-associated thrombosis on tinzaparin by cancer site and frailty: a pooled analysis | PDF",1790089569,23,4,[33,37,42,47],{"page_no":21,"url":34,"width":35,"height":36},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c1a44fd314c92c518b410084cabb9f2a.webp",983,1296,{"page_no":38,"url":39,"width":40,"height":41},2,"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b8c63c51a645e78c8bd0eee211669f57.webp",982,1294,{"page_no":43,"url":44,"width":45,"height":46},3,"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3d61d41241c3fd325582ff8e16c283e3.webp",981,1293,{"page_no":31,"url":48,"width":49,"height":50},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cb823121f0987ca8002f3bc3440cd0a0.webp",980,1292,{"code":4,"msg":52,"data":53},"ok",{"site_id":25,"language":24,"slug":54,"title":13,"keywords":55,"description":14,"schema_data":56,"social_meta":110,"head_meta":112,"extra_data":114,"updated_unix":115},"complications-in-patients-with-cancer-associated-thrombosis-on-tinzaparin-by-cancer-site-and-frailty-a-pooled-analysis","",{"@graph":57,"@context":109},[58,72,92],{"@type":59,"itemListElement":60},"BreadcrumbList",[61,65,68,70],{"item":62,"name":63,"@type":64,"position":21},"https://docshare.wps.com","Home","ListItem",{"item":66,"name":67,"@type":64,"position":38},"https://docshare.wps.com/document/","Document",{"item":69,"name":12,"@type":64,"position":43},"https://docshare.wps.com/document/research-report/",{"item":71,"name":13,"@type":64,"position":31},"https://docshare.wps.com/document/complications-in-patients-with-cancer-associated-thrombosis-on-tinzaparin-by-cancer-site-and-frailty-a-pooled-analysis/350554/",{"url":71,"name":13,"@type":73,"image":74,"author":79,"headline":13,"publisher":81,"fileFormat":84,"inLanguage":24,"description":14,"dateModified":85,"datePublished":86,"encodingFormat":84,"isAccessibleForFree":87,"interactionStatistic":88},"DigitalDocument",{"url":75,"@type":76,"width":77,"height":78},"https://docshare.wps.com/thumbnails/complications-in-patients-with-cancer-associated-thrombosis-on-tinzaparin-by-cancer-site-and-frailty-a-pooled-analysis/350554.png","ImageObject",300,407,{"name":9,"@type":80},"Person",{"url":62,"name":82,"@type":83},"DocShare","Organization","application/pdf","2026-10-30","2026-09-22",true,{"@type":89,"interactionType":90,"userInteractionCount":20},"InteractionCounter",{"@type":91},"ViewAction",{"@type":93,"mainEntity":94},"FAQPage",[95,101,105],{"name":96,"@type":97,"acceptedAnswer":98},"What outcomes were evaluated in CAT patients treated with tinzaparin?","Question",{"text":99,"@type":100},"The analysis evaluated 6-month incidences of recurrent VTE, major bleeding, and death, and compared how these outcomes vary by tumor site and frailty.","Answer",{"name":102,"@type":97,"acceptedAnswer":103},"How was frailty defined for this study?",{"text":104,"@type":100},"Frailty was defined by age ≥75 years, creatinine clearance \u003C50 mL/min, body weight ≤50 kg, or Eastern Cooperative Oncology Group performance status ≥2.",{"name":106,"@type":97,"acceptedAnswer":107},"Do tumor site and frailty affect VTE recurrence and bleeding differently?",{"text":108,"@type":100},"VTE recurrence risk varied by tumor site and frailty, while bleeding risk remained relatively stable across these factors.","https://schema.org",{"og:url":71,"og:type":111,"og:title":13,"og:site_name":82,"og:description":14},"article",{"robots":113,"canonical":71},"index,follow",{"doc_id":7,"site_id":25},1790211417,{"code":4,"msg":5,"data":117},[118,122,126,130,135,140,145,148,152,155,159],{"id":21,"doc_module":4,"doc_module_name":67,"category_name":119,"show_sort_weight":120,"slug":121},"Story & Novel",90,"story-novel",{"id":38,"doc_module":4,"doc_module_name":67,"category_name":123,"show_sort_weight":124,"slug":125},"Literature",80,"literature",{"id":31,"doc_module":4,"doc_module_name":67,"category_name":127,"show_sort_weight":128,"slug":129},"Exam",70,"exam",{"id":131,"doc_module":4,"doc_module_name":67,"category_name":132,"show_sort_weight":133,"slug":134},5,"Comic",60,"comic",{"id":136,"doc_module":4,"doc_module_name":67,"category_name":137,"show_sort_weight":138,"slug":139},6,"Technology",50,"technology",{"id":141,"doc_module":4,"doc_module_name":67,"category_name":142,"show_sort_weight":143,"slug":144},7,"Healthcare",40,"healthcare",{"id":11,"doc_module":4,"doc_module_name":67,"category_name":12,"show_sort_weight":146,"slug":147},30,"research-report",{"id":22,"doc_module":4,"doc_module_name":67,"category_name":149,"show_sort_weight":150,"slug":151},"Religion & Spirituality",20,"religion-spirituality",{"id":150,"doc_module":4,"doc_module_name":67,"category_name":153,"show_sort_weight":150,"slug":154},"World Cup","world-cup",{"id":156,"doc_module":4,"doc_module_name":67,"category_name":157,"show_sort_weight":156,"slug":158},10,"Lifestyle","lifestyle",{"id":160,"doc_module":4,"doc_module_name":67,"category_name":161,"show_sort_weight":131,"slug":162},19,"General","general"]